ENTX Entera Bio Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ENTX

Price (delayed)

$2.16

Market cap

$76.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.31

Enterprise value

$66.01M

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due ...

Highlights
ENTX's quick ratio has surged by 170% since the previous quarter and by 8% year-on-year
The net income is up by 32% year-on-year and by 10% since the previous quarter
The equity has surged by 67% since the previous quarter but it has declined by 12% year-on-year
Entera Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Entera Bio's gross profit has plunged by 100% from the previous quarter and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.enterabio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ENTX
Market
Shares outstanding
35.48M
Market cap
$76.64M
Enterprise value
$66.01M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.99
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$8.86M
EBITDA
-$8.8M
Free cash flow
-$7.33M
Per share
EPS
-$0.31
Free cash flow per share
-$0.25
Book value per share
$0.36
Revenue per share
$0
TBVPS
$0.41
Balance sheet
Total assets
$11.77M
Total liabilities
$1.38M
Debt
$390,000
Equity
$10.39M
Working capital
$10.17M
Liquidity
Debt to equity
0.04
Current ratio
10.32
Quick ratio
10.1
Net debt/EBITDA
1.21
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-83.9%
Return on equity
-101.8%
Return on invested capital
N/A
Return on capital employed
-83%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENTX stock price

How has the Entera Bio stock price performed over time
Intraday
3.35%
1 week
9.09%
1 month
24.86%
1 year
145.48%
YTD
260%
QTD
29.34%

Financial performance

How have Entera Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.94M
Net income
-$8.89M
Gross margin
N/A
Net margin
N/A
Entera Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Entera Bio's gross profit has plunged by 100% from the previous quarter and by 100% YoY
ENTX's operating income is up by 32% year-on-year and by 11% since the previous quarter
The net income is up by 32% year-on-year and by 10% since the previous quarter

Growth

What is Entera Bio's growth rate over time

Valuation

What is Entera Bio stock price valuation
P/E
N/A
P/B
5.99
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 31% year-on-year and by 9% since the previous quarter
ENTX's P/B is 114% above its last 4 quarters average of 2.8 and 46% above its 5-year quarterly average of 4.1
The equity has surged by 67% since the previous quarter but it has declined by 12% year-on-year
Entera Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Entera Bio business performance
ENTX's return on equity is down by 23% year-on-year but it is up by 7% since the previous quarter
Entera Bio's ROA has decreased by 12% YoY but it has increased by 8% from the previous quarter

Dividends

What is ENTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTX.

Financial health

How did Entera Bio financials performed over time
ENTX's quick ratio has surged by 170% since the previous quarter and by 8% year-on-year
The current ratio has surged by 161% since the previous quarter and by 8% year-on-year
The debt is 96% smaller than the equity
The equity has surged by 67% since the previous quarter but it has declined by 12% year-on-year
Entera Bio's debt to equity has decreased by 33% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.